中国P站

Chronic kidney disease (CKD), a condition marked by the progressive loss of renal function over time, affects millions globally and stands as a potent amplifier of cardiovascular risk. Defined by a glomerular filtration rate (GFR) below 60 mL/min/1.73 m² or the presence of kidney damage for at least three months, CKD spans a spectrum from mild impairment to end-stage renal disease (ESRD) requiring dialysis or transplantation. While the kidneys’ role in filtering waste and maintaining fluid balance is well-known, their influence extends far beyond, intricately tied to systemic health, particularly the cardiovascular system. Atherosclerosis, the buildup of lipid-rich plaques within arterial walls, is a leading cause of heart attacks, strokes, and peripheral artery disease, and its progression is markedly accelerated in CKD patients. This accelerated atherosclerosis is not a mere coincidence but a reflection of shared pathophysiological pathways that amplify vascular damage in the context of renal dysfunction. The interplay between these two conditions contributes to a staggering mortality rate, with cardiovascular disease accounting for nearly half of all deaths in CKD patients. This manuscript aims to unravel the complex mechanisms linking CKD to accelerated atherosclerosis, exploring how renal impairment transforms into a vascular crisis and why this relationship demands urgent attention in clinical practice [1].

The escalating prevalence of CKD estimated to affect over 850 million people worldwide mirrors the rising tide of cardiovascular disease, creating a dual epidemic that challenges healthcare systems. Traditional risk factors such as hypertension, diabetes, and dyslipidemia, which predispose individuals to both CKD and atherosclerosis, only partially explain their connection. In CKD, unique factors like uremic toxins, mineral metabolism disorders, and chronic inflammation emerge as powerful accelerators of plaque formation and arterial stiffening [2]. These elements distinguish CKD-related atherosclerosis from its conventional form, often resulting in a more aggressive and diffuse disease pattern. Patients with CKD exhibit not only a higher burden of coronary artery disease but also increased vascular calcification, a hallmark of renal-associated atherosclerosis that complicates treatment. By examining this interplay, this manuscript seeks to illuminate the biological bridges between kidney dysfunction and vascular pathology, offering insights into why CKD patients face such a disproportionate cardiovascular burden and how this knowledge can inform therapeutic strategies [3].

Description

The relationship between CKD and accelerated atherosclerosis is driven by a constellation of mechanisms, with inflammation serving as a central pillar. In CKD, the accumulation of uremic toxins such as indoxyl sulfate and p-cresyl sulfate due to impaired renal clearance triggers a systemic inflammatory response. These toxins activate endothelial cells and macrophages, releasing pro-inflammatory cytokines like interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) [4]. This chronic inflammation damages the arterial endothelium, increasing its permeability to low-density lipoprotein (LDL) cholesterol, which becomes oxidized and engulfed by macrophages to form foam cells the earliest stage of atherosclerotic plaques. Unlike in the general population, where inflammation may wax and wane, CKD sustains this process through persistent uremia, leading to more rapid plaque growth. Moreover, inflammatory mediators in CKD promote vascular smooth muscle cell proliferation and matrix degradation, destabilizing plaques and heightening the risk of rupture and thrombosis. This inflammatory cascade explains why CKD patients experience atherosclerosis at an accelerated pace, often presenting with advanced disease even at younger ages [5].

Mineral metabolism dysregulation, particularly involving calcium and phosphate, further distinguishes CKD-related atherosclerosis. As kidney function declines, phosphate excretion diminishes, leading to hyperphosphatemia, which, alongside elevated fibroblast growth factor-23 (FGF-23) and reduced klotho protein, disrupts mineral homeostasis [6]. This imbalance drives vascular calcification, a process where calcium and phosphate deposit in arterial walls, transforming them from elastic conduits into rigid, plaque-laden structures. Unlike the intimal calcification seen in traditional atherosclerosis, CKD often features medial calcification, affecting the arterial media layer and causing widespread stiffening. This calcification not only accelerates plaque formation but also impairs vasodilation, elevating blood pressure and shear stress additional insults to the vasculature. Studies show that even in early CKD stages, vascular calcification is detectable, progressing dramatically in ESRD, where coronary artery calcium scores can be several-fold higher than in age-matched controls. This mineral dysregulation underscores why CKD patients develop a unique, calcific atherosclerosis that resists conventional interventions like statins, which primarily target lipid-driven plaques [7].

Oxidative stress and endothelial dysfunction amplify the CKD-atherosclerosis nexus. The uremic milieu generates reactive oxygen species (ROS) through impaired antioxidant defenses, such as reduced superoxide dismutase activity. Excess ROS oxidizes LDL, damages endothelial cells, and promotes adhesion molecule expression, facilitating leukocyte infiltration into arterial walls. Endothelial dysfunction, compounded by reduced nitric oxide bioavailability due to uremia and hypertension, impairs vasodilation and fosters a pro-thrombotic state, accelerating plaque progression. Additionally, CKD disrupts lipid metabolism, elevating triglycerides and lowering high-density lipoprotein (HDL) levels, though LDL cholesterol may not always be markedly high. This dyslipidemia, combined with insulin resistance a frequent CKD comorbidity further fuels atherogenesis. The interplay of these factors creates a vicious cycle: atherosclerosis exacerbates renal ischemia, worsening CKD, which in turn intensifies vascular damage. This bidirectional relationship explains the aggressive atherosclerosis seen in dialysis patients, where annual cardiovascular event rates can exceed 20%, far outstripping the general population [8].

Conclusion

The interplay between chronic kidney disease and accelerated atherosclerosis reveals a deadly synergy, where renal dysfunction acts as both a catalyst and amplifier of vascular pathology. Inflammation, mineral metabolism disorders, oxidative stress, and endothelial dysfunction converge to transform CKD into a state of heightened atherogenic risk, producing a distinct and aggressive form of atherosclerosis characterized by widespread calcification and rapid progression. These mechanisms illuminate why CKD patients face cardiovascular mortality rates vastly exceeding those of their non-CKD counterparts, even when traditional risk factors are controlled. The bidirectional nature of this relationship where atherosclerosis further impairs kidney function creates a self-perpetuating cycle that challenges conventional treatment paradigms and underscores the need for integrated management strategies addressing both conditions simultaneously.

From a clinical standpoint, unraveling this interplay highlights the limitations of standard atherosclerosis therapies in CKD. Statins, while effective in reducing lipid-driven plaques, have shown inconsistent benefits in advanced CKD, particularly in dialysis patients, where calcification dominates. Instead, targeting uremic toxins, phosphate levels, and inflammation through dialysis optimization, phosphate binders, or novel anti-inflammatory agents may offer greater promise. Early intervention in CKD, before irreversible vascular damage sets in, is equally critical, as is aggressive management of hypertension and diabetes to break the cycle of mutual reinforcement. Future research should prioritize elucidating the molecular underpinnings of CKD-specific atherosclerosis, potentially identifying biomarkers or therapies to halt its acceleration. The staggering toll of this dual pathology demands a shift in perspective: CKD is not merely a kidney disease but a systemic condition with the vasculature as its battleground. By addressing this interplay head-on, medicine can move toward reducing the cardiovascular burden in CKD, offering patients a chance to defy the grim prognosis that currently defines their journey.

Acknowledgement

None

Conflict of Interest

None

References

1. Zhang L, Reynolds KL, Lyon AR, Palaskas N, Neilan TG (2021) J Am Coll Cardiol Cardio Onc 3: 35-47.

   , ,

2. A Ribas, Wolchok JD (2018) Science 359: 1350-1355.

   , ,

3. Haslam A, Gill J, Prasad V (2020) JAMA Net Open 3: 423.

   , ,

4. Chen DS, Mellman I (2017) Elements of cancer immunity and the cancer-immune set point. Nature 541: 321-330.

   , ,

5. Tang J, Shalabi A, Hubbard-Lucey VM (2018) Ann Oncol 29: 84-91.

   , ,

6. Upadhaya S, Neftelinov ST, Hodge J (2022) Nat Rev Drug Discov 21: 482-483.

   , ,

7. Tang J, Yu JX, Hubbard-Lucey VM, Neftelinov ST, Hodge JP, et al. (2018) Nat Rev Drug Discov 17: 854-855.

   , ,

8. Haslam A, Prasad V (2019) JAMA Net Open 2: 535.

   , ,